Skip to main content

Table 2 Monitoring immunotherapy for GI malignancies

From: Systematic evaluation of immune regulation and modulation

Marker Specimen Use
MSI Tumor Determine eligibility for anti-PD1 treatment
Quant HCV Serum Response to anti-CTLA-4 treatment in patients with HCV infection
Pathology Liver biopsy Rule out drug induced hepatitis
ALT/AST Serum Liver toxicity
Gut microbiome Stool Response to treatment with immune checkpoint inhibitors